Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Artivion, Inc. AORT
$14.72
-$0.02 (-0.14%)
На 18:04, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
604547166.00000000
-
week52high
23.43
-
week52low
9.64
-
Revenue
313789000
-
P/E TTM
-32
-
Beta
1.40865000
-
EPS
-0.46000000
-
Last Dividend
0.39700000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Lake Street | Buy | 08 авг 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| Needham | Buy | Buy | 06 мая 2022 г. |
| Stifel | Buy | 03 мар 2022 г. | |
| Needham | Buy | Buy | 18 февр 2022 г. |
| Oppenheimer | Outperform | Outperform | 26 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 26 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 окт 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Holloway Jean F | A | 124883 | 384 | 24 янв 2023 г. |
| Holloway Jean F | A | 124499 | 866 | 24 янв 2023 г. |
| Stanton Marshall S. | A | 40448 | 443 | 24 янв 2023 г. |
| Stanton Marshall S. | A | 40005 | 810 | 24 янв 2023 г. |
| Maier Dennis B | A | 42465 | 211 | 24 янв 2023 г. |
| Davis John E | A | 111272 | 1228 | 24 янв 2023 г. |
| Horton Amy | D | 99950 | 2000 | 14 дек 2022 г. |
| Horton Amy | D | 101950 | 3226 | 14 дек 2022 г. |
| Barthold Franz Peter | A | 30000 | 30000 | 08 ноя 2022 г. |
| Barthold Franz Peter | A | 32516 | 12511 | 08 ноя 2022 г. |
Новостная лента
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results
PRNewsWire
02 февр 2023 г. в 08:30
ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 financial results will be released on Thursday, February 16, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
25 ноя 2022 г. в 13:33
Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Artivion, Inc. (AORT) Q3 2022 Earnings Call Transcript
Seeking Alpha
05 ноя 2022 г. в 17:02
Artivion, Inc. (NYSE:AORT ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sam Bentzinger - Gilmartin Group Pat Mackin - Chairman, President & CEO Ashley Lee - EVP & CFO Conference Call Participants John McAulay - Stifel Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer & Co. Operator Good day, ladies and gentlemen, and welcome to the Artivion 3Q 2022 Financial Conference Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Sam Bentzinger from the Gilmartin Group.
Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 20:20
Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Seeking Alpha
27 сент 2022 г. в 17:48
Artivion, Inc.'s decision to pull the PROACT Xa trial resulted in heavy downside for the share price. Investors have sold positions rapidly such that the stock trades at multi-year lows.